[Table/Fig-1]:
Patient characteristics and distribution according to PSA/PSAD levels & DRE findings.
| Observation | All Patients | Malignant Disease | Benign Disease | p-value |
|---|---|---|---|---|
| Total patients | 235 | 60 | 175 | - |
| Age (years) | 67.3 (35-89) | 69.01 (35-85) | 66.71 (40-89) | <0.001 |
| Prostate Size (grams) | 60.08 (15-210) | 53.89 (24-180) | 63.06 (15-210) | <0.05 |
| Total PSA (ng/ml)(median) | 13.6 (0.5-2365) |
72.155 (1.06-2365) |
9.93 (0.5-50) |
<0.001 |
| PSA Distribution(ng/ml) • <= 4 • 4 –10 • 10 –20 • 20 –30 • 30 –50 • 50 –100 • > 100 |
10 84 76 22 09 10 24 |
01 05 10 07 03 10 24 |
09 79 66 15 06 0 0 |
- |
| % Free/Total PSA (For PSA 4 – 10) | 13.11 (2.83-31.86) |
12.11 (4.7-28) |
13.09 (2.83-31.86) |
0.494 |
| PSA Density (ng/ml/cm3) | 1.401 (0.007-61.032) |
4.808 (0.025-61.032) |
0.227 (0.017-1.138) |
<0.001 |
| PSA Density distribution (ng/ml/cm3) • <= 0.05 • 0.05-0.1 • 0.1-0.15 • 0.15-0.2 • 0.2 –0.25 • > 0.25 |
12 26 46 30 17 104 |
1 1 2 3 1 52 |
11 25 44 27 16 52 |
- |
| DRE Findings • Suspicious • Normal |
69 166 |
43 17 |
26 149 |
<0.001 |
| Final Management • Radical Prostatectomy • Bilateral Orchidectomy • Chemotherapy + Radiation therapy • Hormonal therapy • TURP • Alpha blocker therapy • Millin’s Prostatectomy • Lost to follow-up after full evaluation |
7 43 5 1 95 78 1 5 |
7 43 5 1 - - - 4 |
- - - - 95 78 1 1 |
- |